JB Pharma Q2 Results: Net profit jumps 16% to Rs 175 crore, revenue up 13%

JB Pharma on Thursday reported a 16% year-on-year (Y-o-Y) jump in net profit to Rs 175 crore for the quarter ended September led by strong growth in domestic formulation business.

The company posted Rs 151 crore in the same quarter last year.

The company’s revenue from operations rose to Rs 1,001 crore in Q2 FY25, a 13 per cent Y-o-Y rise from Rs 882 crore reported in Q2FY24.


JB Pharma’s domestic business grew by 22% YoY to Rs 588 crore, driven by strong demand for products such as Cilacar, Cilacar-T, Rantac, Nicardia, Metrogyl, and Sporlac.

Operating EBITDA grew by 13% to Rs 285 crores, while EBITDA margins remained constant at 28.4%.

Domestic formulations business recorded revenue of Rs 588 crores versus Rs 481 crores growth of 22%. International business revenue grew by 3% at INR 413 crores.

"On the international front, our formulations business performed well in Q2 and CDMO division growth will pick up in H2 as we come out of a seasonally muted Q2," said Nikhil Chopra, CEO and Wholetime Director, JB Pharma.